UNICYCIVE THERAPEUTICS INC (UNCY)
Health Care · Clinical-stage kidney disease therapeutics · NASDAQ
Early-stage kidney disease biotech developing next-generation phosphate binders and acute kidney injury therapies through in-licensed assets.
What UNICYCIVE THERAPEUTICS INC does
Unicycive Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies for kidney disease. The company's pipeline consists of two main programs: oxylanthanum carbonate, a next-generation phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate for acute kidney injury treatment. The company licenses technologies and drugs to pursue development, regulatory approval, and commercialization, with an initial focus on U.S. markets.
Themes: ["Kidney disease / renal therapeutics"]
Fundamentals
- Price$5.26 as of 2026-07-09 close
- Market cap$140M as of 2026-07-10
- 1-year return+9.3% as of 2026-07-09 close
- Net margin-4159.1% as of 2026-07-10
- ROE-131.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.71 as of 2026-07-10
Dividend: pays a dividend.
Key risks (from latest filing)
["Clinical-stage company with no approved products; both oxylanthanum carbonate and UNI-494 remain in early development phases with significant regulatory and clinical risks ahead."]
Competitors & peers
- Keryx Biopharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.